RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
Note: There have been new actions to this contract opportunity. To view the most recent action, please click here.
General Information
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Sep 10, 2024 07:04 am EDT
- Original Response Date: Oct 18, 2024 01:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date: Nov 02, 2024
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code:
- NAICS Code:
- Place of Performance: DCUSA
Description
This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) titled, "NextGen Oral Formulation Vaccines for COVID-19". The purpose of this effort is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, improve our understanding of their potential, and to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. The full RPP and information on joining the consortium can be accessed through the RRPV website at www.rrpv.org.
Attachments/Links
Contact Information
Primary Point of Contact
- Rebecca Harmon
- rebecca.harmon@ati.org